Top Markets
#1 Cortex Cortex +33.66%
#2 Seeker Seeker +20.06%
#3 Ethena Staked ENA Ethena Staked ENA +10.21%
#4 Official Trump Official Trump +9.41%
#5 EXOD EXOD +9.04%
#6 peaq peaq +8.30%
#7 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +7.70%
#8 MarsCoin MarsCoin +7.36%
#9 Solstice Solstice +6.35%
#10 Versatize Coin Versatize Coin +5.26%
Coin of the day
Cortex Cortex
Settings
Language
ENGLISH
Currency
USD
Theme
Hugel, Inc. Hugel, Inc.

Hugel, Inc.

145020
Rank in Stocks #6806
Hugel, Inc. is a biopharmaceutical firm headquartered in Chuncheon-si, South... Hugel, Inc. is a biopharmaceutical firm headquartered in Chuncheon-si, South Korea, with a presence both domestically and internationally. The company specializes in the development and manufacturing of diverse medical solutions. A primary product is its Botulinum Toxin, presented as a clear glass vial containing a white, injectable dry powder. This therapeutic is prescribed for several conditions: treating essential eyelid spasms in adults over 18; ameliorating severe frown lines linked to corrugator and/or procerus muscle activity in adults aged 18 to 65; managing upper limb spasticity following a stroke; and correcting dynamic equinus foot deformity in children with cerebral palsy aged over 2. Furthermore, it aids in improving the lateral canthal lines (crow's feet) caused by orbicularis oculi muscle activity in adults between 19 and 65. This product is marketed under various labels, including Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot. Hugel also provides hyaluronic acid dermal fillers, known as Dermalax and The Chaeum; cosmetic products under the Wellage brand; and medical devices distributed as BlueRose. Hugel, Inc. commenced operations in 2001.
Share Price
$170.80
Market Cap
$1.85B
Change (1 day)
0.61%
Change (1 year)
-25.35%
Country
KR
Trade Hugel, Inc. (145020)

Category

Healthcare
P/E ratio for Hugel, Inc. (145020)
P/E ratio as of 2026 TTM: 0
According to Hugel, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Hugel, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.